Regulated Necrosis in Atherosclerosis. Issue 11 (22nd September 2022)

• Record Type: Journal Article
• Authors: Puylaert, Pauline; Zurek, Michelle; Rayner, Katey J.; De Meyer, Guido R.Y.; Martinet, Wim
• Is Part Of: Arteriosclerosis, thrombosis, and vascular biology. Volume 42:Issue 11(2022)
• Page Start: 1283
• Page End: 1306
• Publication Date: 2022-09-22
• Subjects: atherosclerosis -- ferroptosis -- necroptosis -- necrosis -- pyroptosis; Arteriosclerosis -- Periodicals; Thrombosis -- Periodicals; Blood-vessels -- Pathophysiology -- Periodicals; Electronic journals; 616.13
• DOI: 10.1161/ATVBAHA.122.318177
• Languages: English
• ISSNs: 1079-5642

Abstract

Abstract : During atherosclerosis, lipid-rich plaques are formed in large- and medium-sized arteries, which can reduce blood flow to tissues. This situation becomes particularly precarious when a plaque develops an unstable phenotype and becomes prone to rupture. Despite advances in identifying and treating vulnerable plaques, the mortality rate and disability caused by such lesions remains the number one health threat in developed countries. Vulnerable, unstable plaques are characterized by a large necrotic core, implying a prominent role for necrotic cell death in atherosclerosis and plaque destabilization. Necrosis can occur accidentally or can be induced by tightly regulated pathways. Over the past decades, different forms of regulated necrosis, including necroptosis, ferroptosis, pyroptosis, and secondary necrosis, have been identified, and these may play an important role during atherogenesis. In this review, we describe several forms of necrosis that may occur in atherosclerosis and how pharmacological modulation of these pathways can stabilize vulnerable plaques. Moreover, some challenges of targeting necrosis in atherosclerosis such as the presence of multiple death-inducing stimuli in plaques and extensive cross-talk between necrosis pathways are discussed. A better understanding of the role of (regulated) necrosis in atherosclerosis and the mechanisms contributing to plaque destabilization may open doors to novel pharmacological strategies and will enable clinicians to tackle the residual cardiovascular risk that remains in many atherosclerosis patients.